Cargando…
The role of globalization in drug development and access to orphan drugs: orphan drug legislation in the US/EU and in Latin America
Compared to a decade ago, nearly three times as many drugs for rare diseases are slated for development. This article addresses the market access issues associated with orphan drug status in Europe and the United States in contrast to the legislation in five Latin American (LA) countries that have m...
Autores principales: | Arnold, Renée J.G., Bighash, Lida, Bryón Nieto, Alejandro, Tannus Branco de Araújo, Gabriela, Gay-Molina, Juan Gabriel, Augustovski, Federico |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
F1000Research
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4367514/ https://www.ncbi.nlm.nih.gov/pubmed/25844162 http://dx.doi.org/10.12688/f1000research.4268.1 |
Ejemplares similares
-
Orphans in the Market: The History of Orphan Drug Policy
por: Mikami, Koichi
Publicado: (2019) -
Leveraging existing opportunities for improved Orphan Drug approval in the EU
por: Edfjäll, Catarina
Publicado: (2012) -
Access to Orphan Drugs is a Challenge for Sustainable Management of Cystinosis in China
por: Li, Xiao-Qiao, et al.
Publicado: (2018) -
Estimating the clinical cost of drug development for orphan versus non-orphan drugs
por: Jayasundara, Kavisha, et al.
Publicado: (2019) -
Reimbursement Legislations and Decision Making for Orphan Drugs in Central and Eastern European Countries
por: Malinowski, Krzysztof Piotr, et al.
Publicado: (2019)